drugset / Trial / NCT07466927

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

NCT07466927

Phase 2 Not yet recruiting 30 enrolled Fudan University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective, open-label, phase II platform trial. The purpose of this study is to test the safety and effectiveness of multi-mode thermal therapy combined with immunotherapy in patients with HER2-negative breast cancer with liver metastases who had previously received systemic therapy

Timeline

Start
2026-03-15
Primary completion
2028-01-15
Completion
2029-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody Intravenous
Subject Pembrolizumab Monoclonal antibody Intravenous
Subject Sacituzumab Tirumotecan Other / unclassified Intravenous
Subject Trastuzumab Rezetecan Monoclonal antibody Intravenous